Filana Therapeutics Expects Patient Screening In Phase 2a Study Of Simufilam In TSC-Related Epilepsy To Begin By Q1 2027, Following FDA Lift Of Clinical Hold In September

Loading news article.

Filana Therapeutics Expects Patient Screening In Phase 2a Study Of Simufilam In TSC-Related Epilepsy To Begin By Q1 2027, Following FDA Lift Of Clinical Hold In September | WAPE

Filana Therapeutics Expects Patient Screening In Phase 2a Study Of Simufilam In TSC-Related Epilepsy To Begin By Q1 2027, Following FDA Lift Of Clinical Hold In September

Article summary

Related companies

Analyzed by WAPE AI.

Comments —